Bellaire Dermatology Announces it is Recruiting Patients for Psoriasis and Acne Cyst Clinical Trials

Bellaire Dermatology is recruiting patients for two clinical trials as part of their ongoing efforts to offer innovative and effective dermatology treatments. The first trial is for a drug called AMAGINE-3, which treats severe psoriasis plaques. The second study is the use of Acleara for treaing acne cysts. Patients interested in this study should contact the office for additional information.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
This procedure may be able to help patients who are unable to achieve therapeutic goals with the existing treatment options for psoriasis.

Bellaire, TX (PRWEB) November 14, 2012

Bellaire Dermatology is recruiting patients for two clinical trials as part of their ongoing efforts to offer innovative and effective dermatology treatments. The first trial is for a drug called AMAGINE-3, which treats severe psoriasis plaques. The second study is the use of Acleara for treaing acne cysts. Patients interested in this study should contact the office for additional information.

The psoriasis study is currently in phase 3 of the clinical trial for the AMAGINE-3 investigational psoriasis medication known as brodalumab. Brodalumab (new IL-17 blocker) is a type of protein that blocks the interaction of other proteins in the body that can cause inflammation and symptoms related to psoriasis. Although there are several types of psoriasis, approximately 80 percent of patients have plaque psoriasis, which can cause painful and itchy red, scaly patches to appear on the skin. Bellaire Dermatology is recruiting patients from 18 to 75 years of age that have been diagnosed with moderate to severe plaque psoriasis for at least six months prior to this trial.

"Bellaire Dermatology is excited to assist with conducting this dermatology clinical research trial here at our research center in Houston," says Dr. Craig Teller. "This procedure may be able to help patients who are unable to achieve therapeutic goals with the existing treatment options for psoriasis."

The second trial currently available at Bellaire Dermatology is for Acleara. This system has already been approved by the FDA to treat mild inflammation for acne using light and vacuum technology. It both removes sebaceous material that causes acne as well as light to destroy the bacteria responsible for acne. Bellaire Dermatology is conducting a clinical trial to examine the effects of the Acleara system on acne cysts. Interested patients should call (713) 661-4383 or email clinicaltrials(at)bda-derm(dot)com to learn more.

Bellaire Dermatology is a leading cosmetic, surgical and medical dermatology office in Houston, Texas. The practice specializes in dermatology services including acne treatment, Botox, Juvederm, injectable fillers, cosmetic fillers, vein treatments, CoolSculpting, laser resurfacing, and Mohs Surgery. Bellaire Dermatology offers personalized treatment plans and the most current and effective dermatological therapies available.


Contact